Artificial neural network modeling to predict the plasma concentration of aminoglycosides in burn patients

Biomedicine and Pharmacotherapy

Volumn 58, Issue 4, 2004, Pages 239-244

  Yamamura, Shigeo ^a   Kawada, Keiko ^a   Takehira, Rieko ^a   Nishizawa, Kenji ^b   Katayama, Shirou ^b   Hirano, Masaaki ^b   Momose, Yasunori ^a  

^a TOHO UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

Author keywords

Aminoglycoside antibiotics; Artificial neural network modeling; Burn severity; Pharmacokinetic modeling

Indexed keywords

AMINOGLYCOSIDE; HABEKACIN;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BODY MASS; BURN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MALE; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; SKIN GRAFT;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BURNS; DIBEKACIN; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER);

EID: 2942562882     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.12.012     Document Type: Article

References (25)

1. Cynober L., Prugnaud O., Lioret N., Duchemin C., Saizy R., Giboudeau J. Serum transthyretin levels in patients with burn injury. Surgery. 109:1991;640-644
2. Munster A.M. Immunologic response of trauma and burns. An overview. Am J Med. 76:1984;142-145
3. Pruitt B.A. Jr, McManus A.T., Kim S.H., Goodwin C.W. Burn wound infections: current status. World J Surg. 22:1998;135-145
4. Sood P., Mandal A., Mishra B. Postantibiotic effect of a combination of antimicrobial agents on pseudomonas aeruginosa. Chemotherapy. 46:2000;173-176
5. Weinbren M.J. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother. 44:1999;319-327
6. Zaske D.E., Bootman J.L., Solem L.B., Strate R.G. Increased burn patient survival with individualized dosage of gentamicin. Surgery. 91:1982;142-149
7. Bartal C., Danon A., Schlaeffer F., Reisenberg K., Alkan M., Smoliakov R., et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 114:2003;194-198
8. Shagel L., Yu A. Applied biopharmaceutics and pharmacokinetics. 4th ed:1999;732 Appleton-Lange
9. Zaske D.E., Cipolle R.J., Strate R.J. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery. 87:1980;164-169
10. Polk R.E., Mayhall C.G., Smith J., Hall G., Kline B.J., Swensson E., et al. Gentamicin and tobramycin penetration into burn eschar. Pharmacokinetics and microbiological effects. Arch Surg. 118:1983;295-302
11. Rougier F., Claude D., Maurin M., Sedoglavic A., Ducher M., Corvaisier S., et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother. 47:2003;1010-1016
12. Fanvelle F., Coulaud J.M., Lecointre K., Tardy D., Poussel J.F., Trape G. Comparison of two methods to obtain a desired first isepamicin peak in intensive care patients. Fundam Clin Pharmacol. 15:2001;151-156
13. Nishizawa K., Hirano M., Kimura A., Mochizuki T., Yamamoto Y., Yamamura S., et al. Administration of aminoglycosides antibiotics for critically ill patients. Pharmacometrics. 64:2003;15-21
14. Yamamura S. Clinical application of artificial neural networks to predict pharmacokinetic parameters of severe ill patients. Adv Drug Deliv Rev. 55:2003;1233-1251
15. Yamamura S., Takehira R., Kawada K., Nishizawa K., Katayama S., Hirano M., et al. Application of artificial neural network modeling to identify severely ill patients whose aminoglycoside concentration is likely to fall below therapeutic concentrations. J Clin Pharm Therapeut. 28:2003;425-432
16. Agatonovic-Kustrin A., Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J Pharm Biomed Anal. 22:2000;717-727
17. Takayama K., Fujiwara M., Nagai T. Artificial neural network as a novel method to optimize pharmaceutical formulations. Pharm Res. 15:1999;1-6
18. Kim Y.S., Sohn S.Y., Yoon C.N. Screening test data analysis for liver disease prediction model using growth curve. Biomed Pharmacother. 57:2003;482-488
19. Smith B.P., Brier M.E., Brian P. Statistical approach to neural network model building for gentamicin peak predictions. J Pharm Sci. 85:1996;65-69
20. Brier M.E., Aronoff G.R. Application of artificial neural networks to clinical pharmacology. Int J Clin Phamacol Therapeut. 34:1996;510-514
21. Shepherd A.J. Second-order methods for neural networks. 1997;Springer, New York
22. Ogawa M. Mechanisms of development of the organ failure following surgical insult. The 'second attack' theory. Clin Intensive Care. 7:1996;34-38
23. Cumming J. Objective estimates of the incidence and the consequences of multiple organ dysfunction and sepsis after burn trauma. J Trauma. 50:2001;510-515
24. Edwards D.F., Hollingsworth H., Zazulia A.R., Diringer M.N. Artificial neural networks improve the prediction of mortality in intracerebral hemorrhage. Neurology. 53:1999;351-357
25. Clermont G., Angus D.C., DiRusso S.M., Griffin M., Linde-Zwirble W.T. Predicting hospital mortality for patients in the intensive care unit: a comparison of artificial neural networks with logistic regression models. Crit Care Med. 29:2001;291-296